NASDAQ:LSB Lakeshore Biopharma (LSB) Stock Price, News & Analysis $2.29 -0.11 (-4.58%) Closing price 04/2/2025 03:40 PM EasternExtended Trading$2.30 +0.00 (+0.22%) As of 04/2/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lakeshore Biopharma Stock (NASDAQ:LSB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lakeshore Biopharma alerts:Sign Up Key Stats Today's Range$2.20▼$2.3450-Day Range$1.85▼$2.7852-Week Range$1.81▼$11.20Volume9,502 shsAverage Volume20,023 shsMarket Capitalization$21.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Read More… Remove Ads Lakeshore Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreLSB MarketRank™: Lakeshore Biopharma scored higher than 11% of companies evaluated by MarketBeat, and ranked 903rd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lakeshore Biopharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioLakeshore Biopharma has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lakeshore Biopharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of Lakeshore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeshore Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakeshore Biopharma has recently decreased by 1.37%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakeshore Biopharma does not currently pay a dividend.Dividend GrowthLakeshore Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the float of Lakeshore Biopharma has been sold short.Short Interest Ratio / Days to CoverLakeshore Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lakeshore Biopharma has recently decreased by 1.37%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Lakeshore Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakeshore Biopharma insiders have not sold or bought any company stock.Percentage Held by Institutions52.64% of the stock of Lakeshore Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lakeshore Biopharma's insider trading history. Receive LSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakeshore Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LSB Stock News HeadlinesLSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27thFebruary 6, 2025 | businesswire.comLakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial ApprovalDecember 19, 2024 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 3, 2025 | Paradigm Press (Ad)LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year GuidanceDecember 19, 2024 | prnewswire.comLakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 13, 2024 | finanznachrichten.deLakeShore Biopharma Faces Challenges Amid Criminal Probe into Former ChairmanDecember 12, 2024 | markets.businessinsider.comLakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 12, 2024 | globenewswire.comLakeShore Biopharma Co Ltd Ordinary SharesNovember 23, 2024 | morningstar.comSee More Headlines LSB Stock Analysis - Frequently Asked Questions How have LSB shares performed this year? Lakeshore Biopharma's stock was trading at $3.46 at the start of the year. Since then, LSB stock has decreased by 33.8% and is now trading at $2.29. View the best growth stocks for 2025 here. When did Lakeshore Biopharma's stock split? Lakeshore Biopharma's stock reverse split on Friday, October 4th 2024. The 1-10 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Lakeshore Biopharma? Shares of LSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lakeshore Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lakeshore Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Today4/03/2025Next Earnings (Estimated)4/18/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LSB Previous SymbolNASDAQ:LSB CIK1946399 WebN/A Phone17327133678FaxN/AEmployees773Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.13 Current Ratio1.17 Quick Ratio0.90 Sales & Book Value Annual Sales$672.27 million Price / Sales0.03 Cash FlowN/A Price / Cash FlowN/A Book Value$8.86 per share Price / Book0.26Miscellaneous Outstanding Shares9,306,000Free FloatN/AMarket Cap$21.31 million OptionableN/A Beta0.68 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:LSB) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.